drugset
drugset / Trial / NCT01093040

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

NCT01093040 ↗

Phase 1 Completed 30 enrolled MedImmune LLC AstraZeneca · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

To assess the safety of the administration of the drug (CAT-354) in healthy Japanese subjects.

Timeline

Start
2010-04
Primary completion
2010-05
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tralokinumab Monoclonal antibody 150 mg Subcutaneous
Subject Tralokinumab Monoclonal antibody 300 mg Subcutaneous
Subject Tralokinumab Monoclonal antibody 600 mg Subcutaneous

Indications

No indication recorded.